表紙
市場調查報告書

肺炎球菌疫苗:流行病學的預測 (∼2028年)

Pneumococcal Vaccines: Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 920864
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
肺炎球菌疫苗:流行病學的預測 (∼2028年) Pneumococcal Vaccines: Epidemiology Forecast to 2028
出版日期: 2019年11月30日內容資訊: 英文 37 Pages
簡介

全球主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 的兒童肺炎球菌疫苗接種率預計至2028年以約85%穩定發展。另一方面,老年人的接種率預計除了法國的6個國家停留在稍微擴大,至2028年成為62%。

本報告提供全球主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 的肺炎球菌疫苗的市場調查,疾病的背景,風險要素、並存症,疫苗接種率的變化、預測,侵入性肺炎鏈球菌感染 (IPD)的診斷患者數等各種資料彙整

第1章 目錄

第2章 肺炎球菌疫苗:摘要整理

第3章 流行病學

  • 疾病的背景
  • 風險要素、並存症
  • 全球趨勢
    • 兒童、成人肺炎球菌疫苗接種率
    • 侵入性肺炎球菌感染:診斷罹患患者數
  • 預測手法
  • 流行病學的預測:肺炎球菌疫苗、侵入性肺炎球菌感染
    • 已接種兒童人口
    • 已接種成人人口
    • IPD診斷罹患患者數
    • IPD診斷罹患患者數:各年齡
  • 討論

第4章 附錄

目錄
Product Code: GDHCER226-19

Pneumococcal Vaccination rates in children are expected to remain steady at approximately 85% in the combined seven major markets (7MM - The US, France, Germany, Italy, Spain, the UK and Japan) by 2028, while vaccination rates in the elderly are expected to slightly increase to only 62% in the combined six major markets (6MM - The US, Germany, Italy, Spain, the UK and Japan) by 2028.

Streptococcus pneumoniae (S. pneumoniae) is a bacterial organism that causes a number of diseases, ranging from serious to mild infections. Symptoms depend on the part of the body that is infected, and range from fever, chills, and difficulty breathing to stiff neck and confusion. Transmission of S. pneumoniae primarily occurs through respiratory droplets. The term invasive pneumococcal disease (IPD) refers to more severe infections in which the bacterium is isolated from normally sterile sites. IPD is most common in high-risk groups, such as young children and the elderly, where the immune system is more vulnerable.

With pediatric pneumococcal vaccination, the primary reason for non-vaccination is vaccine hesitancy. In contrast, with elderly vaccination, the primary reason for non-vaccination is a lack of awareness about the pneumococcal vaccine from both the patient and healthcare professional. While pediatric rates are promising, there is still room for improvement. Addressing vaccine hesitancy requires further investigation and analysis into specific social, behavioral and economic factors that play a role in whether or not an individual gets vaccinated.

Furthermore, to help overcome insufficient doctor-patient communication and knowledge about vaccines, incentives or certifications should be offered to doctors who remain up-to-date on national vaccine guidelines and who are properly trained in vaccine counseling. In the future, continued efforts should focus on carrying out a targeted, actionable, and effective country-specific approach to overcome vaccine hesitancy, increase vaccine awareness, and ultimately reduce invasive pneumococcal disease incidence worldwide.

The latest research report "Pneumococcal Vaccines: Epidemiology Forecast to 2028" provides an overview of the risk factors and global trends of pneumococcal vaccines in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). Epidemiologists have utilized comprehensive, country-specific pneumococcal vaccination rate data and IPD diagnosed incidence rate data from nationally representative public health surveillance systems and databases to arrive at a meaningful, in-depth epidemiological analysis and forecast. Moreover, epidemiologists have provided detailed dose- and age-specific pneumococcal vaccination rates that are dependent on the routine immunization requirements of each market within this report.

Scope

  • The Pneumococcal Vaccines Epidemiology Report provides an overview of the risk factors and global trends of pneumococcal vaccines in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the vaccinated pneumococcal population segmented by age (pediatric and elderly), and diagnosed incident cases of IPD segmented by age (0-4 years, 5-9 years, 10-19 years, and by 10-year age groups up to 80 years and older). Pneumococcal vaccine dosing and age groups included within the forecast were dependent on the routine immunization requirements in each market and the availability of vaccination data. In addition, the epidemiology model corresponding to this report provides IPD diagnosed incident cases segmented into the top ten most common IPD serotypes by age (pediatric and elderly).
  • The Pneumococcal Vaccines epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Pneumococcal Vaccines Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global pneumococcal vaccines market.
  • Quantify patient populations in the global pneumococcal vaccines market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for pneumococcal vaccine therapeutics in each of the markets covered.
  • Understand magnitude of the pneumococcal vaccines population by dose and age.

Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Pneumococcal Vaccines: Executive Summary

  • 2.1 Related Reports
  • 2.2 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
    • 3.3.1 Pediatric and Elderly Pneumococcal Vaccination Rates
    • 3.3.2 Diagnosed Incidence of Invasive Pneumococcal Disease (Cases per 100,000 Population)
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Sources Not Used
    • 3.4.3 Forecast Assumptions and Methods
    • 3.4.4 Pneumococcal Vaccination Rates in the Pediatric Population
    • 3.4.5 Pneumococcal Vaccination Rates in the Elderly Population
    • 3.4.6 Diagnosed Incident Cases of Invasive Pneumococcal Disease
  • 3.5 Epidemiological Forecast for Pneumococcal Vaccines and Invasive Pneumococcal Disease (2018-2028)
    • 3.5.1 Pneumococcal Vaccinated Pediatric Population
    • 3.5.2 Pneumococcal Vaccinated Elderly Population
    • 3.5.3 Diagnosed Incident Cases of IPD
    • 3.5.4 Age-Specific Diagnosed Incident Cases of IPD
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Invasive Pneumococcal Disease
  • Table 2: Pediatric Pneumococcal Vaccination Rate Trends (%)
  • Table 3: Elderly Pneumococcal Vaccination Rate Trends (%)

List of Figures

  • Figure 1: 7MM, Pneumococcal Vaccinated Pediatric Population, Both Sexes, 2018 and 2028
  • Figure 2: 6MM, Pneumococcal Vaccinated Elderly Population, Both Sexes, 2018 and 2028
  • Figure 3: 7MM, Diagnosed Incident Cases of IPD, Both Sexes, All Ages, 2018 and 2028
  • Figure 4: 7MM, Diagnosed Incidence of IPD, Both Sexes, All Ages, 2008*2028
  • Figure 5: 7MM, Sources Used for the Pneumococcal Vaccinated Pediatric Population
  • Figure 6: 6MM, Sources Used for the Pneumococcal Vaccinated Elderly Population
  • Figure 7: 7MM, Sources Used for the Diagnosed Incident Cases of IPD
  • Figure 8: 7MM, Pneumococcal Vaccinated Pediatric Population, Both Sexes, 2018
  • Figure 9: 6MM, Pneumococcal Vaccinated Elderly Population, Both Sexes, 2018
  • Figure 10: 7MM, Diagnosed Incident Cases of IPD, Both Sexes, All Ages, 2018
  • Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of IPD, Men and Women, 2018
Back to Top